WebJun 2, 2024 · Background: BTX-1188 is a first-in-class oral molecular glue that degrades GSPT1 and IKZF1/3 and is currently in phase 1 clinical trials for treatment of hematologic and solid malignancies. Targeted protein degradation of cereblon neosubstrates is clinically validated in the treatment (tx) of hematologic malignancies (Lu 2014, Zou 2024).
BioTheryX Receives IND Clearance from FDA to Proceed with
WebJul 2, 2024 · Tones and I - Dance Monkey (Lyrics) Cloudx Music 2.04M subscribers Subscribe Share 175M views 2 years ago #DanceMonkey #DanceMonkeylyrics #TonesAndI Tones and I - Dance Monkey (Lyrics) ⏬ Stream... WebThe Extron TPX 88 A twisted pair matrix switcher works in conjunction with Extron twisted pair transmitters and receivers to provide simplified routing of signals ranging from … dj lost one
BTX-1188 / BioTheryX - LARVOL
WebBTX-1188, a first-in-class dual degrader of GSPT1 and IKZF1/3, for treatment of acute myeloid leukemia (AML) and solid tumors. (ASCO 2024) - "This approach is expected to improve clinical outcomes and reduce toxicities associated with pure GSPT1 degradation (CC-90009), thus expanding the therapeutic window of BTX-1188. WebJun 4, 2024 · Preclinical data demonstrated potential for using the first-in-class oral molecular glue BTX-1188 in patients with solid tumors or acute myeloid leukemia (AML) and greater sensitivity in MYC dependent/high disease and is now being investigated in phase 1 clinical trials, according to a poster presented at the 2024 American Society of Clinical … WebBTX-1188 is the first ever rationally designed dual-targeting molecular glue degrader of GSPT1 and IKZF1/3 that we are developing for the treatment of acute myeloid leukemia … dj lona atikku